Fibrotic liver disease

This study tests a drug called hydronidone in 300 adults with liver scarring (fibrosis or cirrhosis) from chronic hepatitis B. Participants take the drug three times daily for 28 days to see if it is safe. The main goal is to track any side effects.

This study tests a drug called hydronidone in 150 adults with liver scarring caused by chronic hepatitis B. Participants take the capsules three times daily for 28 days. The main goal is to check for side effects and ensure the drug is safe. This is an early-phase trial, so it fo…

This study tests an experimental drug called AZD2389 in people with liver fibrosis (scarring) and compensated cirrhosis (early-stage liver damage). The goal is to check the drug's safety and how the body handles it. About 40 adults with liver disease will receive either AZD2389 o…

This study tested whether adding prazosin, a drug usually used for high blood pressure, to standard hepatitis C treatment could reduce liver scarring. 112 adults with chronic hepatitis C (genotype 1 or 4) and severe liver fibrosis took part. Researchers measured changes in liver …

This early-phase study tested an oral drug called idebenone in 53 adults with non-alcoholic steatohepatitis (NASH) and mild-to-moderate liver scarring. The main goal was to check safety and tolerability, while also looking for signs that the drug might reduce liver stiffness and …

This study tested whether a combination of two drugs, dasatinib and quercetin, can reduce liver scarring in people with non-alcoholic fatty liver disease (NAFLD) and fibrosis. Thirty adults with biopsy-confirmed liver scarring took either the drug combo or a placebo in cycles ove…

This study tested whether giving growth hormone to people with decompensated liver cirrhosis (advanced liver scarring) could improve their health and survival. The trial included 96 adults with this condition. Researchers measured how long patients survived without major complica…

This phase 2b trial tested whether saroglitazar magnesium can help people with nonalcoholic steatohepatitis (NASH) and liver fibrosis. 189 adults took either a 2 mg or 4 mg dose of the drug or a placebo daily for several months. The main goal was to see if the drug could resolve …

This study is testing whether a common blood test, called FIB4, can help find people with advanced liver fibrosis (serious liver scarring) who don't know they have it. About 500 adults aged 18-70 with a high FIB4 result will get a more detailed liver check, including a special ul…

This study investigates whether non-invasive imaging techniques—ultrasound and MRI—can accurately diagnose non-alcoholic steatohepatitis (NASH) and liver fibrosis in people with fatty liver disease. Currently, a liver biopsy is the gold standard, but it is invasive and carries ri…

This study tests a new ultrasound-based device called the Liver Incytes System to see if it can measure liver stiffness and fat as accurately as MRI and FibroScan. The device uses sound waves to create images of the liver, similar to a traditional ultrasound. Researchers are enro…

This study explores whether a simple breath test can detect early liver fibrosis in people with non-alcoholic steatohepatitis (NASH). Participants fast overnight, then drink a mixture of food-grade flavor compounds and provide breath samples over 90 minutes. The way the body proc…

This study looked at whether a breath test could help detect liver fibrosis, cirrhosis, or liver cancer. Researchers collected breath samples from 56 patients with known or suspected liver disease and analyzed them for specific chemical markers. The goal was to see if the test co…

This study tested a new, fully automated MRI technique to diagnose liver fibrosis and inflammation without needing a needle biopsy or contrast dye. Researchers scanned 200 adults with chronic liver disease and compared the MRI results to standard biopsy findings. The goal is to p…

This study tested whether a noninvasive device called FibroScan can accurately measure liver scarring (fibrosis) in children, potentially replacing the need for a liver biopsy. Researchers compared FibroScan results with biopsy results in 264 children aged 6 months to 18 years wi…

This study tested whether an artificial intelligence (AI) tool, called ACE 2.0, can detect undiagnosed liver cirrhosis by analyzing a routine electrocardiogram (ECG). Researchers at Mayo Clinic enrolled 279 primary care clinicians and their adult patients. The AI flagged ECGs tha…

This study looked at 100 children with beta-thalassemia major and iron overload to see if simple blood tests (ferritin and hepcidin) can detect liver scarring (fibrosis) as accurately as other non-invasive methods. Researchers measured these blood markers and compared them to ult…

This early-stage trial tested whether a single dose of hydronidone, an experimental drug for liver fibrosis, changes the heart's electrical activity (QTc interval) in 48 healthy Chinese adults. Participants received one of three doses or a placebo, and researchers measured how th…

This study looks at how the drug hydronidone moves through the body in people with different levels of liver function. Thirty adults with either normal liver function or varying degrees of liver impairment will take a single dose of the drug. The goal is to understand how liver h…

This study looked at liver fibrosis (scarring) in 127 HIV patients who had high liver enzymes while on antiretroviral therapy. Participants underwent tests like liver biopsy, ultrasound, and CT scans to measure liver damage. The goal was to understand how common and severe liver …

This early study tests whether a single dose of the experimental drug AZD2389 can attach to a protein called FAP in the liver. Twelve adults with advanced liver scarring (fibrosis) will get a PET scan before and after taking the drug to see if it binds to its target. The goal is …

This completed study looked at how often hospitalized patients with cirrhosis experience pain. Researchers asked 30 patients about their pain, its location, intensity, and whether it was chronic. The goal was to highlight an often-overlooked issue and encourage better pain care f…

This study follows adults in Zambia who have both HIV and chronic hepatitis B to track liver health over up to 10 years. Researchers aim to understand how current HIV treatments affect hepatitis B and liver damage, and to identify factors that lead to serious outcomes like liver …

This study followed 326 adults in Zambia with chronic hepatitis B for up to 5 years. Researchers tracked how the virus behaves, how many patients need treatment, and how many develop serious liver problems like cirrhosis or liver cancer. The goal was to better understand the dise…

This study looked at 315 HIV-positive adults to build models that predict fatty liver disease and liver scarring. Researchers used ultrasound and FibroScan tests to track liver changes over time. The goal was to better understand and identify liver problems early in people living…

This study tested a new ultrasound technique called ARFI to measure liver stiffness in 109 people, including healthy volunteers and patients with liver conditions. The goal was to understand normal stiffness values and how they change with disease or treatment. This is an observa…

This study tested new MRI and MRE techniques that let children breathe normally during scans, instead of holding their breath. The goal was to measure liver fat and stiffness more comfortably and accurately in kids with fatty liver disease. 135 children aged 6-17 took part, and t…

This study looked at over 5,000 adults in Zambia to find out how many have hepatitis B and how many need treatment. Researchers tested people in their homes and then did more tests on those who tested positive. The goal was to gather information, not to test a new treatment or cu…

This study followed 215 people newly diagnosed with HIV in Hong Kong to see how often they developed non-AIDS conditions like high blood pressure, diabetes, bone thinning, and kidney problems. Participants were on different anti-retroviral regimens, and researchers compared the r…